NASDAQ · HAE

Haemonetics Corporation

Healthcare · Medical - Instruments & Supplies

$106.24

Up+$0.04 (+0.04%)

Updated Sep 17, 2026, 2:41 AM

SID Score

6.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap: 4.12B
P/E ratio: 23.87
Dividend yield: 0.00%
52-week range: $47.32 – $109.57
Volume: 520.72K
Avg. volume: 976.76K

Price performance

HAE price history

1M range · 19 trading sessions · Daily adjusted prices

Last close: $106.20
Period change: -2.04%
Period low: $101.06
Period high: $108.80

Daily close

View OHLC price history

HAE OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Sep 15, 2026	$105.14	$106.87	$103.24	$106.20	440.03K
Sep 14, 2026	$106.98	$107.47	$102.835	$106.31	887.94K
Sep 11, 2026	$101.70	$102.89	$100.53	$102.69	458.31K
Sep 10, 2026	$102.02	$102.95	$100.595	$101.06	602.32K
Sep 9, 2026	$102.15	$103.18	$100.57	$103.16	612.22K
Sep 8, 2026	$101.89	$103.525	$101.25	$102.84	581.59K
Sep 4, 2026	$101.59	$103.565	$101.51	$102.92	425.09K
Sep 3, 2026	$103.69	$104.05	$101.73	$102.85	602.06K
Sep 2, 2026	$102.24	$104.37	$101.61	$102.92	777.67K
Sep 1, 2026	$103.60	$104.16	$101.08	$101.95	633.65K
Aug 31, 2026	$103.06	$103.95	$101.39	$103.07	494.69K
Aug 28, 2026	$104.59	$105.61	$103.57	$103.96	659.23K
Aug 27, 2026	$105.73	$106.515	$104.59	$105.00	592.86K
Aug 26, 2026	$107.75	$108.08	$106.42	$106.60	661.29K
Aug 25, 2026	$108.13	$108.68	$106.8391	$108.32	502.18K
Aug 24, 2026	$108.02	$109.49	$107.375	$108.40	641.06K
Aug 21, 2026	$109.24	$109.5707	$107.00	$108.80	582.12K
Aug 20, 2026	$106.84	$109.555	$106.49	$108.22	891.22K
Aug 19, 2026	$105.20	$108.50	$105.01	$108.41	1.46M

Latest HAE news

The latest Smart Investors Daily articles mentioning HAE.

analystAug 20, 2026

Barrington Research Reiterates Outperform Rating on Haemonetics Corporation (HAE)

sec filingAug 19, 2026

HAEMONETICS CORP (HAE) Reports Material Event to SEC

analystAug 18, 2026

BTIG Reiterates Buy Rating on Haemonetics Corporation (HAE)

Latest HAE news

The latest Smart Investors Daily articles mentioning HAE.

Stock researchCompany · Overview

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

HAE research

Overview

Company profile and research snapshot.

Company profile

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: —
Average target: $82.00
Implied upside: —
Analysts: —

HAE recent ratings
Date	Firm	Rating	Target
Sep 3, 2026	Raymond James	Outperform	—
Aug 21, 2026	Baird	Outperform	—
Aug 19, 2026	Barrington Research	Outperform	—
Aug 18, 2026	BTIG	Buy	—
Aug 7, 2026	JP Morgan	Neutral	—

Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 23, 2026

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation

Benzinga · Feb 23, 2026

Haemonetics Receives FDA Clearance For NexSys PCS Plasma Collection System

Yahoo · Feb 20, 2026

Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET.

Yahoo · Feb 18, 2026